|
An overview of targets and therapies for glioblastoma multiforme
Gayathri Chandrasekar1, Vinay Scheel Bansal2, Manas Panigrahi3, Satish S Kitambi4
1 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden
2 Department of Translational Sciences, Institute for Healthcare Education and Translational Sciences, Secunderabad, Telengana, India
3 Department of Neurosurgery, Krishna Institute of Medical Sciences, Hyderabad, Telengana, India
4 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden; Department of Translational Sciences, Institute for Healthcare Education and Translational Sciences, Secunderabad, Telengana, India
Correspondence Address:
Satish S Kitambi
Institute for Healthcare Education and Translational Sciences, 10-2-311, Plot 187, Str4, Cama Manor, West Marredpally, Secunderabad - 500 026, Telengana
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jcrt.jcrt_1324_21
|
|
Glioblastoma multiforme (GBM) affects individuals above 65 years of age and has low median survival rate. Due to limited treatment options, lack of effective diagnosis, and palliative care, there is an urgent need to develop new therapeutic strategies to combat GBM. This review provides an overview of the current clinical trial scenario with a special focus on new targets, repurposed drugs, and technologies in the field of GBM. The use of technological advances and artificial intelligence in diagnosis and imaging is also discussed. In addition, this review also highlights the need to design a dynamic palliative care strategy for end-of-life management of patients with GBM.
|
